###begin article-title 0
Brain dystrophin-glycoprotein complex: Persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
Aside from muscle, brain is also a major expression site for dystrophin, the protein whose abnormal expression is responsible for Duchenne muscular dystrophy. Cognitive impairments are frequently associated with this genetic disease, we therefore studied the fate of brain and skeletal muscle dystrophins and dystroglycans in dystrophic animal models.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 114 117 114 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 594 597 581 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 602 605 589 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 692 695 679 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
All dystrophin-associated glycoproteins investigated were reduced in dystrophic muscle fibres. In Dp427-deficient mdx brain and Dp71-deficient mdx-3cv brain, the expression of alpha-dystroglycan and laminin was reduced, utrophin isoforms were up-regulated and beta-dystroglycan was not affected. Immunofluorescence localization of beta-dystroglycan in comparison with glial, endothelial and neuronal cell markers revealed co-localization of von Willebrand factor with beta-dystroglycan. Its expression at the endothelial-glial interface was preserved in dystrophin isoform-deficient brain from mdx and mdx-3cv mice. In addition, chemical crosslinking revealed that the Dp71 isoform exists in mdx brain predominantly as a monomer.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
This suggests an association of beta-dystroglycan with membranes at the vascular-glial interface in the forebrain. In contrast to dystrophic skeletal muscle fibres, dystrophin deficiency does not trigger a reduction of all dystroglycans in the brain, and utrophins may partially compensate for the lack of brain dystrophins. Abnormal oligomerization of the dystrophin isoform Dp71 might be involved in the pathophysiological mechanisms underlying abnormal brain functions.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 195 197 195 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 719 720 704 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 753 754 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 768 769 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 784 785 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 796 797 764 765 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 810 811 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 844 845 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 859 861 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 883 885 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 978 979 939 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1144 1146 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1287 1289 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1495 1497 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
The main hypotheses of how deficiency in dystrophin triggers muscular dystrophy suggest that the lack of this membrane cytoskeletal component weakens the sarcolemmal integrity, causes abnormal Ca2+-homeostasis and/or impairs proper clustering of ion channel complexes [1, 2]. Extensive biochemical and cell biological studies have demonstrated that one of the major functions of muscle dystrophin is to act as an actin-binding protein which mediates a link between the extracellular matrix component laminin and the sub-sarcolemmal membrane cytoskeleton [3,4]. Integral or surface-associated proteins that are relatively tightly connected with dystrophin are represented by alpha-,beta-, gamma-, and delta-sarcoglycan [5], alpha- and beta-dystroglycan [6], sarcospan [7], alpha-, beta1-, and beta2-syntrophin [8], alpha- and beta-dystrobrevin [9], laminin-2 [10] and cortical actin [11]. The backbone of this sarcolemma-spanning protein assembly is formed by the dystroglycans [6]. The extreme carboxy-terminus of 43 kDa beta-dystroglycan contains a binding site for the second half of the hinge-4 region and the cysteine-rich domain of Dp427 [12], thereby indirectly connecti ng the actin membrane cytoskeleton via the amino-terminus of the dystrophin molecule to the surface membrane [13]. Since beta-dystroglycan is also tightly associated with the peripheral merosin-binding protein alpha-dystroglycan, this complex provides a stable linkage to the laminin alpha2-chain in the basal lamina [10].
###end p 8
###begin p 9
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 347 350 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 674 676 674 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1176 1177 1176 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1342 1344 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1346 1348 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 351 356 <span type="species:ncbi:10090">mouse</span>
###xml 1334 1340 <span type="species:ncbi:9606">humans</span>
Deficiency in dystrophin triggers the disintegration of complexes normally formed by the above listed sarcolemmal components and thereby renders muscle fibres from patients afflicted with Duchenne muscular dystrophy (DMD) more susceptible to necrosis [1, 3]. In analogy to the pathobiochemical findings in DMD [3, 14], the dystrophic animal model mdx mouse also exhibits a drastic reduction in all dystrophin-associated glycoproteins in bulk skeletal muscle [15, 16]. This might explain at least partially the decreased osmotic stability [17] and higher vulnerability of stretch-induced injury [18] in dystrophin-deficient muscle fibres. An abnormal increase in cytosolic Ca2+- levels might trigger a drastic inc rease in net protein degradation and might be one of the initial steps in the molecular pathogenesis of inherited muscular dystrophy [19,20,21]. That the other members of the dystrophin -glycoprotein complex, besides dystrophin, play a role in the DMD pathology, is demonstrated by the fact that primary abnormalities in sarcoglycans and laminin are responsible for certain forms of limb-girdle muscular dystrophy and congenital muscular dystrophy, respectively [5, 22]. In contrast to muscle, much less is known about the molecular mechanisms underlying brain abnormalities in the most frequent neuromuscular disease in humans [23, 24]. One factor which probably makes pathophysiological studies of the dystrophic central nervous system more difficult is the greater complexity of dystrophin and utrophin isoforms present in the brain.
###end p 9
###begin p 10
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1145 1147 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1292 1294 1292 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1338 1340 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1342 1344 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1409 1411 1409 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1438 1440 1438 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1669 1671 1669 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1758 1760 1758 1760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1949 1952 1949 1952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 2012 2014 2012 2014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 2052 2055 2052 2055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 2184 2186 2184 2186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 2378 2380 2378 2380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2382 2384 2382 2384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 2385 2387 2385 2387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 2388 2390 2388 2390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 1953 1958 <span type="species:ncbi:10090">mouse</span>
###xml 2060 2065 <span type="species:ncbi:10090">mouse</span>
Seven promoters drive the tissue-specific expression of various dystrophin protein (Dp) isoforms from the human DMD gene [25], i.e. Dp427-M in skeletal and cardiac muscle, Dp427-B in brain, Dp427-P in Purkinje neurons, Dp-260 R in retina, Dp -140 - B/K in brain and kidney, Dp -116-S in Schwann cells, Dp-71-B/U in brain and many non-muscle tissues [13]. In addition, dystrophin-related proteins are represented by brain DRP-2 [26] and the autosomally-encoded dystrophin homologue utrophin, which forms a full-length 395 kDa isoform (Up395) [27] and two truncated molecular species named Up116 and Up71, also referred to as G-and U-utrophin [28]. Besides full-length brain Dp427 and a relatively low-abundance, carboxy-terminal isoform termed brain Dp140, in the central nervous system the major dystrophin isoform is represented by Dp71 [23]. While Dp427 was shown to be present in cortical neurons, hippocampal neurons and cerebellar Purkinje cells [29], probably mostly associated in these cell types with the postsynaptic density [30], the two smaller dystrophin brain isoforms were described to be associated with microvasular glial cells [31]. A developmental study suggests that dystrophin expression in perivascular astrocytes coincides with the formation of the blood-brain barrier [32]. Dystroglycans are also present in brain [33, 34] and a subpopulation localizes to the glial-vascular interface [31]. Recently, Blake et al. [35] showed that different dystrobrevin isoforms are present in neuronal versus glial dystrophin complexes. With respect to dystrophin-related proteins, full-length utrophin is more widely distributed in the central nervous system [36] and is possibly involved in the maintenance of regional specialization of the brain [37]. To complement these neurobiological studies and in order to determine the fate of dystroglycans in dystrophin-deficient forebrain, we employed two established genetic animal models. The mdx mouse is missing Dp427 due to a point mutation in exon 23 [38], while a mutation in exon 65 in the mdx-3cv mouse affects the splicing of both the 4.8 and 14 kb dystrophin mRNAs resulting in the additional loss of the Dp71 isoform [39]. Neurobehavioral studies have shown that the dystrophic animal models used in this study exhibit moderate alterations in associative learning and deficits in long-term consolidation memory [24, 40,41,42]. Our analysis of these mutant strains indicates that beta-dystroglycan appears to be located at the endothelial-glial interface in the forebrain and that not all dystroglycans are reduced in dystrophic brain, making it different from dystrophic muscle fibres. Possibly an impaired oligomerization of the major brain Dp71 isoform plays a role in the molecular pathogenesis in the dystrophic central nervous system.
###end p 10
###begin title 11
Results
###end title 11
###begin p 12
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 1077 1079 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1260 1263 1253 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1268 1271 1261 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1327 1329 1320 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1360 1362 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1384 1386 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
In contrast to muscle tissues, relatively little is known about the function of brain dystrophins and their associated glycoproteins. To provide the necessary background for the rationale behind this study, the complexity of the dystrophin-glycoprotein complex, the structure and isoform expression pattern of dystrophins and the suitability of dystrophic animal models is summarized in Fig. 1. Dystrophin was previously shown to exist as a large multimeric complex at the cell periphery. As illustrated in the diagrammatic representation of Fig. 1a, the dystroglycan sub-complex provides the backbone structure of this plasmalemma-spanning complex thereby providing a linkage between the extracellular matrix and the membrane cytoskeleton [3, 22]. While the Dp427(-M) isoform exists in skeletal muscle, the central nervous system contains additional shorter dystrophin molecules [13, 25]. Three dystrophin isoforms exist in brain: Dp427(-B), Dp140 and Dp71 (Fig. 1b). Since they all share carboxy-terminal domains, antibodies against this region recognize all three isoforms [23]. In order to determine the effect of the absence of dystrophin on the dystrophin-associated glycoproteins alpha- and beta-dystroglycan, we have used the established animal models mdx and mdx-3cv. These genetic models are due to a point mutation [38] and a genetic rearrangement [39], respectively (Fig. 1c).
###end p 12
###begin p 13
###xml 0 174 0 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Diagrammatic representation of the dystrophin-glycoprotein complex, the structure of muscle and brain dystrophin isoforms and the genetic animal models of muscular dystrophy.</bold>
###xml 1477 1480 1455 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1541 1544 1519 1522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1481 1485 <span type="species:ncbi:10090">mice</span>
###xml 1549 1553 <span type="species:ncbi:10090">mice</span>
Diagrammatic representation of the dystrophin-glycoprotein complex, the structure of muscle and brain dystrophin isoforms and the genetic animal models of muscular dystrophy. In muscle, dystrophin forms a tightly associated complex with various surface components which provides a stabilizing linkage between the sub-sarcolemmal membrane cytoskeleton and the extracellular matrix. In panel (a) is shown the proposed spatial organization of this peripheral complex consisting of dystrophin (Dp427), alpha-, beta-, gamma-, and delta-sarcoglycan (SG), the sarcolemma-spanning backbone structure provided by alpha- and beta-dystroglycan (DG), sarcospan (SS), various syntrophins (SYN) and dystrobrevins (DB), as well as laminin-2 (LAM-2) and cortical actin. Panel (b) outlines the various domains of dystrophin molecules with the N-terminal actin-binding domain (AB), hinge regions (H), the central spectrin-like rod domain (RD), as well as C-terminal binding domains such as the WW domain, the ZZ domain, the cysteine-rich region (CR) and the extreme carboxy-terminal domain (CD). While skeletal muscle fibres contain the Dp427 isoform of dystrophin, brain tissues express besides the full-length Dp427 molecule also two shorter isoforms termed Dp71 and Dp140 (b). Four of the seven promoters which drive the tissue-specific expression of dystrophins are shown in panel (c) illustrating that a point mutation in exon 23 or a mutation in exon 65 results in the absence of Dp427 in mdx mice and the absence of all brain isoforms of dystrophin in mdx-3cv mice.
###end p 13
###begin p 14
###xml 187 190 187 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 195 198 195 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 586 596 575 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a,d,g,j,s</xref>
###xml 675 677 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2m</xref>
###xml 793 795 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2n</xref>
###xml 844 847 829 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 852 855 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 932 936 917 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2k,l</xref>
###xml 1037 1045 1015 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e,f,h,i</xref>
###xml 1087 1091 1061 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2t,u</xref>
###xml 1118 1122 1092 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2o,q</xref>
###xml 1158 1162 1128 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2p,r</xref>
###xml 1412 1414 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1440 1444 1410 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2v-x</xref>
###xml 574 579 <span type="species:ncbi:10090">mouse</span>
For comparative purposes and in order to characterize the genetic animal models of muscular dystrophy used in this study, the fate of dystrophin-associated glycoproteins was evaluated in mdx and mdx-3cv skeletal muscle fibres and forebrain. Using indirect immunofluorescence microscopy, it was clearly shown that alpha- and beta-dystroglycan are greatly reduced in muscle cells from both animal models. Antibodies to laminin, dystrophin, alpha-sarcoglycan and both members of the dystroglycan sub-complex almost exclusively immunolabeled the muscle cell periphery in normal mouse (Fig. 2a,d,g,j,s). Utrophin staining was restricted to the neuromuscular junction region (Fig. 2m) and overlapped with the visualization of the nicotinic acetylcholine receptor by alpha-bungarotoxin binding (Fig. 2n). In stark contrast, in cryosections taken from mdx and mdx-3cv skeletal muscle, which exhibited a complete absence of dystrophin (Fig. 2k,l), a greatly reduced immunofluorescence signal was detectable for alpha- and beta-dystroglycan (Fig. 2e,f,h,i), as well as for alpha-sarcoglycan (Fig. 2t,u). Utrophin staining (Fig. 2o,q), alpha-bungarotoxin binding (Fig. 2p,r), and laminin labeling (2b, c) was not affected in dystrophic fibres. In control experiments, cryosections were labeled with antibodies to the membrane cytoskeletal protein spectrin, a component established not to be affected in muscular dystrophy [14]. As can be seen in Fig. 2v-x, both normal muscle and fibres from both dystrophic animal models exhibit almost exclusively peripheral staining for spectrin establishing the integrity of the cryosections analysed.
###end p 14
###begin p 15
###xml 0 135 0 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunofluorescence localization of &#946;-dystroglycan and associated components in skeletal muscle fibres from dystrophic animal models.</bold>
###xml 596 599 563 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 634 637 601 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 565 569 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
Immunofluorescence localization of beta-dystroglycan and associated components in skeletal muscle fibres from dystrophic animal models. Shown are cryosections labeled with antibodies to laminin (LAM) (a-c), alpha-dystroglycan (alpha-DG) (d-f), beta-dystroglycan (beta-DG) (g-i), the carboxy-terminus of dystrophin (C-DYS) (j-l), utrophin (UTR) (m, o, q), alpha-sarcoglycan (alpha-SG) (s-u), and spectrin (SPE) (v-x). Panels (n), (p) and (r) represent labeling of tissue sections with alpha-bungarotoxin (alpha-BGT). Skeletal muscle specimens were taken from normal mice (a, d, g, j, m, n, s, v), mdx mice (b, e, h, k, o, p, t, w) and mdx-3cv mice (c, f, i, l, q, r, u, x). Bar = 60 mum.
###end p 15
###begin p 16
###xml 399 400 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 686 688 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 690 692 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 831 833 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 953 955 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1011 1013 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1138 1140 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 1470 1474 1455 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3e,f</xref>
###xml 1443 1446 <span type="species:ncbi:10116">rat</span>
Since initial immunofluorescence labeling experiments with antibodies to beta-dystroglycan resulted in a distinct staining pattern in forebrain tissue, we performed more detailed co-localization experiments. Double-staining with antibodies to various common brain cell type markers revealed that this surface glycoprotein is highly enriched at the endothelial-glial interface in the forebrain (Fig. 3). As labels for distinct markers of glial, neuronal and endothelial cells we employed monoclonal antibody NR4 against the neurofilament of apparent 68 kDa, polyclonal antibody GA5 to the glial fibrillary acidic protein and a polyclonal antibody to von Willebrand factor, respectively [43, 44]. The neuronal marker strongly labeled this cell type but did not exhibit an overlap with the staining pattern of beta-dystroglycan (Fig. 3a). In contrast, contact zones of overlapping staining were evident between beta-dystroglycan and the glial marker (Fig. 3b), probably representing glial endfeet structures (Fig. 3c). A high degree of overlapping immunolabeling was clearly evident between von Willebrand factor and beta-dystroglycan (Fig. 3d). Since antibodies to von Willebrand factor specifically label endothelial cells, this suggests high levels of beta-dystroglycan at the endothelial-glial interface. To document the specificity of the antibody used for labeling von Willebrand factor, the restricted staining of the endothelial layer in rat aorta is shown in Fig. 3e,f.
###end p 16
###begin p 17
###xml 0 88 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Colocalization of &#946;-dystroglycan and von Willebrand factor in normal mouse forebrain.</bold>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 477 480 <span type="species:ncbi:10116">rat</span>
Colocalization of beta-dystroglycan and von Willebrand factor in normal mouse forebrain. Shown are cryosections indirectly labeled with rhodamine-conjugated antibodies to the neurofilament of apparent 68 kDa (a), the glial fibrillary acidic protein (b, c) and von Willebrand factor (d). Sections (a) to (d) were indirectly double-labeled with a fluorescein-conjugated antibody against beta-dystroglycan. To demonstrate the specificity of the antibody to von Willebrand factor, rat aorta sections are shown in (e) (Haematoxylin & Eosin staining) and (f) (immunofluorescence labeled). In (a), bar = 20 mum; in (b) and (d), bar = 40 mum; in (c), bar = 10 mum; and in (e) and (f), bar = 60 mum.
###end p 17
###begin p 18
###xml 248 252 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4j-l</xref>
###xml 315 318 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 322 325 319 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 370 374 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a-i</xref>
###xml 642 645 632 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 741 743 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4k</xref>
###xml 902 905 892 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 926 928 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4l</xref>
###xml 1069 1073 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4m-o</xref>
###xml 330 335 <span type="species:ncbi:10090">mouse</span>
Following the immunolocalization of beta-dystroglycan in normal forebrain, we analysed the relative expression levels of dystrophin and associated components by immunofluorescence microscopy in dystrophic forebrain. In contrast to dystrophin (Fig. 4j-l), dystroglycan labelling was not reduced in cryosections from mdx or mdx-3cv mouse forebrain. As illustrated in Fig. 4a-i, the intensity and pattern of immuno staining for laminin, alpha-dystroglycan and beta-dystroglycan was not affected in the dystrophic specimens studied. Labeling with domain-specific antibodies to dystrophin revealed the presence of Dp71 and the absence of Dp427 in mdx forebrain, since the antibody to the carboxy terminus showed a distinct labeling pattern (Fig. 4k) while the probe to the rod domain did not stain any structures (not shown). All dystrophin isoforms which share the carboxy terminal domain were absent from mdx-3cv forebrain (Fig. 4l). Utrophin exhibited a similar localization pattern to dystrophin and was present in the forebrain from both dystrophic animal models (Fig. 4m-o).
###end p 18
###begin p 19
###xml 0 122 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunofluorescence localization of &#946;-dystroglycan and associated components in forebrain from dystrophic animal models.</bold>
###xml 407 410 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 436 439 419 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
Immunofluorescence localization of beta-dystroglycan and associated components in forebrain from dystrophic animal models. Shown are cryosections labeled with antibodies to laminin (LAM) (a-c), alpha-dystroglycan (alpha-DG) (d-f), beta-dystroglycan (beta-DG) (g-i), the carboxy-terminus of dystrophin (C-DYS) (j-l), and utrophin (UTR) (m-o). Forebrain specimens were taken from normal mice (a, d, g, j, m), mdx mice (b, e, h, k, n) and mdx-3cv mice (c, f, i, l, o). Bar = 40 mum.
###end p 19
###begin p 20
###xml 272 275 272 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 280 283 280 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 451 454 451 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 557 560 557 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 746 750 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b-d</xref>
###xml 828 831 817 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 836 839 825 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 868 870 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5e</xref>
###xml 923 926 912 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 934 936 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 938 940 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 942 944 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1037 1040 1026 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1444 1445 1429 1430 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1642 1644 1627 1629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5f</xref>
###xml 927 932 <span type="species:ncbi:10090">mouse</span>
###xml 1053 1058 <span type="species:ncbi:10090">mouse</span>
To determine potential differences in the fate of dystrophin-associated surface components in dystrophic muscle and brain tissues, we also performed a comparative immunoblot analysis of components of the dystrophin-glycoprotein complex using the established animal models mdx and mdx-3cv. As illustrated in the immunoblot analysis shown in Fig. 5, the expression levels of laminin were not affected in the microsomal fraction isolated from dystrophic mdx muscle. On the other hand, this extracellular protein is clearly increased in its relative density in mdx-3cv membranes (Fig. 5a). Both, alpha- and beta-dystroglycan, as well as alpha-sarcoglycan were found to be drastically reduced in their abundance in both dystrophic animal models (Fig. 5b-d). The dystrophin isoform Dp427 was demonstrated to be completely absent from mdx and mdx-3cv muscle microsomes (Fig. 5e). These findings agree with previous studies on the mdx mouse [15, 16, 22] and show that the same reduction in dystrophin-associated glycoproteins also occurs in the mdx-3cv genetic mouse model. Immunolabeling of full-length utrophin of apparent 395 kDa did not result in sufficient immuno-decoration for a proper comparison of its expression levels in normal versus dystrophic muscle membranes (not shown). For control purposes, an identical immunoblot as was used for the analysis of the dystrophin-glycoprotein complex, was immuno-decorated with an antibody to the alpha1-subunit of the dihydropyridine receptor. The relative abundance of this transverse-tubular membrane protein does not seem to be affected in microsomes isolated from dystrophic muscle fibres (Fig. 5f). Thus, the decrease in dystrophin-associated glycoproteins in skeletal muscle is a specific resu lt of the deficiency of dystrophin, and not a consequence of general muscle cell destruction in dystrophic fibres.
###end p 20
###begin p 21
###xml 0 115 0 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunoblot analysis of &#946;-dystroglycan and associated components in normal and dystrophic skeletal muscle fibres.</bold>
###xml 366 367 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 414 415 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 507 510 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 523 526 490 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
Immunoblot analysis of beta-dystroglycan and associated components in normal and dystrophic skeletal muscle fibres. Shown are identical immunoblots labeled with antibodies to laminin (LAM) (a), alpha-dystroglycan (alpha-DG) (b), beta-dystroglycan (beta- DG) (c), alpha-sarcoglycan (alpha-SG) (d), full-length dystrophin of apparent 427 kDa (Dp427) (e), and the alpha1-subunit of the dihydropyridine receptor (alpha1-DHPR) (f). Lanes 1 to 3 represent microsomal membranes isolated from normal muscle fibres, mdx fibres, and mdx-3cv fibres, respectively. The position of immuno-decorated protein bands is indicated by arrow heads.
###end p 21
###begin p 22
###xml 279 282 279 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 293 296 293 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 711 714 711 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 723 726 723 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 764 780 764 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Maclura pomifera</italic>
###xml 800 816 800 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tritium vulgaris</italic>
###xml 1149 1152 1145 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1169 1173 1165 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a,b</xref>
###xml 1245 1248 1238 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1253 1256 1246 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1290 1292 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7c</xref>
###xml 1389 1391 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 1539 1541 1528 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7d</xref>
###xml 1569 1572 1558 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1716 1717 1705 1706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1879 1882 1868 1871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1910 1914 1899 1903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7f,g</xref>
###xml 1998 2000 1987 1989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7e</xref>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 764 780 <span type="species:ncbi:3496">Maclura pomifera</span>
###xml 1157 1162 <span type="species:ncbi:10090">mouse</span>
Following the analysis of microsomes from dystrophic muscle, we determined the relative expression levels of dystrophin and associated components by immunoblotting in total brain membranes. Prior to this comprehensive immunoblot analysis, membrane preparations from normal mice, mdx brain and mdx-3cv brain were compared by Coomassie staining and lectin overlay assays. Fig. 6 shows that the overall protein band pattern and lectin staining of distinct populations of glycoproteins was relatively comparable between the three different preparations. The only major difference between normal and dystrophic microsomes is the appearance of two protein bands of approximately 50 kDa in membranes isolated from the mdx and the mdx-3cv disease model. Staining with the Maclura pomifera lectin MPA and the Tritium vulgaris lectin WGA demonstrates that the deficiency in brain dystrophin isoforms does not trigger a general reduction in microsomal glycoproteins. In contrast, laminin and alpha-dystroglycan were clearly shown to be reduced in their relative expression in total brain microsomes from dystrophic animals, which is especially apparent in the mdx-3cv mouse (Fig. 7a,b). Interestingly, beta-dystroglycan expression was not affected in both mdx and mdx-3cv total brain microsomes (Fig. 7c), which is a stark contrast to its drastic reduction in dystrophic skeletal muscle fibres (Fig. 5c). Since alpha-sarcoglycan does not exist in brain, the abundance of members of the sarcoglycan subcomplex were not studied. The immunoblot of Fig. 7d confirms the status of the mdx-3cv brain and demonstrates the absence of the Dp71 isoform in this animal model. In analogy to previous studies on dystrophic skeletal muscle [3], certain utrophin isoform levels were found to be elevated in Dp427-deficient and Dp71-deficient brain specimens. Both Up116 and Up71 were greatly increased in mdx-3cv brain microsomes (Fig. 7f,g), while full-length utrophin did not seem to be affected in dystrophic brain (Fig. 7e).
###end p 22
###begin p 23
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of microsomal preparations from normal, <italic>mdx</italic> and <italic>mdx</italic>-3cv brain.</bold>
###xml 151 167 151 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tritium vulgaris</italic>
###xml 191 207 191 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Maclura pomifera</italic>
###xml 296 299 296 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 311 314 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 395 397 395 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-3</sup>
###xml 191 207 <span type="species:ncbi:3496">Maclura pomifera</span>
Analysis of microsomal preparations from normal, mdx and mdx-3cv brain. Shown is a Coomassie-stained gel (CB) (a) and identical blots labeled with the Tritium vulgaris lectin WGA (b) and the Maclura pomifera lectin MPA (c). Lanes 1 to 3 represent microsomal membranes isolated from normal brain, mdx brain, and mdx-3cv brain, respectively. The relative position of molecular mass standards (x 10-3) is indicated on the left.
###end p 23
###begin p 24
###xml 0 108 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunoblot analysis of &#946; dystroglycan and associated components in normal and dystrophic brain-membranes.</bold>
###xml 533 536 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 548 551 531 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
Immunoblot analysis of beta dystroglycan and associated components in normal and dystrophic brain-membranes. Shown are identical immunoblots labeled with antibodies to laminin (LAM) (a), alpha-dystroglycan (alpha-DG) (b), beta-dystroglycan (beta-DG) (c), dystrophin of apparent 71 kDa (Dp71) (d), full-length utrophin of apparent 395 kDa (Up395) (e), the utrophin isoform of apparent 116 kDa (Up116) (f), and the utrophin isoform of apparent 71 kDa (Up71) (g). Lanes 1 to 3 represent microsomal membranes isolated from normal brain, mdx brain, and mdx-3cv brain, respectively. The position of immuno-decorated protein bands is indicated by arrow heads.
###end p 24
###begin p 25
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8a</xref>
###xml 734 737 734 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8b</xref>
###xml 999 1006 999 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx-3cv</italic>
###xml 1421 1422 1417 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1424 1425 1420 1421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1569 1571 1565 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8d</xref>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
Since dystrophin does not exist in isolation at the cell surface but forms tightly associated multimeric complexes [3], it was of interest to determine the oligomeric status of the major brain isoform Dp71 in normal and dystrophic mice. Using previously optimized crosslinking conditions [45], we employed the hydrophilic 1.14 nm probe BS3 to stabilize high-molecular-mass complexes. The Coomassie-stained gel in Fig. 8a illustrates that incubation with the crosslinker did not trigger general protein clustering since the protein band pattern was relatively comparable between control and crosslinked membranes. On the other hand, a clear difference was observed for crosslinking-stabilized Dp71 complex formation between normal and mdx brain microsomes. While the crosslinker probe induced a shift to a high-molecular-mass complex in control samples, no decrease in electrophoretic mobility was detectable in dystrophic membranes (Fig. 8b). The major dystrophin isoform Dp71 was not detectable in mdx-3cv microsomes. Interestingly, crosslinking-induced complex formation of full-length utrophin was observed in normal brain, as well as in both dystrophic animal models studied (8c). Therefore, protein-protein int eractions between brain components and utrophin do not appear to be affected in dystrophic tissues. For control purposes, an identical immunoblot was labeled with an antibody to the alpha-subunit of the Na+/K+-ATPase. No shift to an extremely high-molecular-mass complex was observed for this brain surface protein following chemical crosslinking (Fig. 8d). This strongly suggests that the decrease in the relative electrophoretic mobility of Dp71 in normal brain microsomes is a specific result of crosslinker-induced stabilization of native membrane complexes.
###end p 25
###begin p 26
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 0 87 0 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chemical crosslinking analysis of brain dystrophin isoform Dp71 in normal and <italic>mdx</italic> mice.</bold>
###xml 317 318 313 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 320 321 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 473 474 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 590 593 581 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 605 608 596 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 847 849 838 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-3</sup>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Chemical crosslinking analysis of brain dystrophin isoform Dp71 in normal and mdx mice. Shown is a Coomassie-stained gel (a) and identical immunoblots labeled with antibodies to the dystrophin isoform of apparent 71 kDa (Dp71) (b), full-length utrophin of apparent 395 kDa (Up395) (c), and the alpha-subunit of the Na+/K+-ATPase (alpha-NKA) (d). Lanes 1, 3 and 5 represent untreated control samples (-) and lanes 2, 4 and 6 are membranes treated with 200 mug crosslinker BS3 per mg protein (+). Lanes 1 and 2, 3 and 4, and 5 and 6 represent microsomal membranes isolated from normal brain, mdx brain, and mdx-3cv brain, respectively. The position of immuno-decorated monomers is indicated by closed arrow heads and crosslinking-stabilized high-molecular-mass complexes marked by open arrows. The relative position of molecular mass standards (x 10-3) is indicated on the left.
###end p 26
###begin title 27
Discussion
###end title 27
###begin p 28
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1124 1126 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 209 217 <span type="species:ncbi:9606">children</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">children</span>
###xml 769 777 <span type="species:ncbi:9606">children</span>
###xml 922 926 <span type="species:ncbi:9606">boys</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
Although the X-linked inherited disorder Duchenne muscular dystrophy (DMD) is primarily considered a muscle disease and most patients die of respiratory or cardiac failure [46], in a subpopulation of affected children non-progressive mental retardation preceeds degeneration of the muscular system [24]. These mental abnormalities do not correlate with the stage of the muscle disease [47] and can not be attributed to abnormal motor development [46]. Since all DMD patients experience a decrease in strength of limb and torso muscles, but only approximately one-third of dystrophic children suffer from cognitive impairments, it is believed that differences exist in the pathophysiolgical mechanisms between the central nervous system and muscle tissues [23, 24]. DMD children accomplish performance tasks at a normal level, but their verbal intelligence quotient is significantly lower as compared to age-matched normal boys [48]. Possibly cerebral or cerebellar hypermetabolism is involved in cognitive impairments in certain DMD patients [49], but no consistent abnormalities are detectable in dystrophic brain tissues [50].
###end p 28
###begin p 29
###xml 636 638 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 640 642 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 644 646 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 647 649 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 650 652 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 653 655 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 864 866 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 867 869 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 870 872 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 873 875 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1035 1038 1029 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1070 1077 1064 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx-3cv</italic>
###xml 1121 1124 1115 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1231 1232 1222 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1234 1236 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1238 1240 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1634 1636 1614 1616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1398 1402 <span type="species:ncbi:10090">mice</span>
Based on this lack of understanding of the exact neurobiology of DMD, we have performed here a comparative analysis of the expression of dystrophins and dystroglycans in brain and muscle tissues from animal models of muscular dystrophy. Forebrain beta-dystroglycan was clearly shown to co-localize with the endothelial marker von Willebrand factor and it is not drastically affected in its relative abundance in brain lacking all neuronal dystrophin isoforms. The localization of this relatively abundant glycoprotein at the endothelial-glial interface agrees with previous immunolocalization studies on dystrophin-associated proteins [31, 32, 51,52,53,54]. Dystrophin isoforms of varying length, dystrobrevin and beta-dystroglycan appear to be enriched around blood vessels in astrocytic endfeet in the cerebellum and at blood-ocular barrier sites in the retina [51,52,53,54]. Here we can show that the cellular localization of this integral membrane component at the endothelial-glial interface is neither changed in Dp427-deficient mdx forebrain or in Dp71-deficient mdx-3cv forebrain. Thus, in contrast to dystrophic mdx and DMD skeletal muscle fibres, which show a greatly reduced expression of sarcolemmal beta-dystroglycan [3, 15, 16], this usually dystrophin-associated glycoprotein experiences a different fate during pathophysiological changes in the central nervous system of dystrophic mice. However, the relative expression of alpha-dystroglycan is reduced in dystrophic brain. This is unexpected, since both alpha- and beta-dystroglycan are produced by post-translational cleavage of the product of a single transcript [10]. Although beta-dystroglycan expression is preserved, this integral membrane protein might not be properly positioned in order to anchor extracellular alpha-dystroglycan to the outside of the membrane. Compensatory mechanisms to counteract the loss of dystrophin isoforms may induce conformational changes in beta-dystroglycan units that interfere with stablising interactions within dystroglycan sub-complexes. Therefore, the preservation of beta-dystroglycan does not seem to rescue the extracellular dystroglycan form.
###end p 29
###begin p 30
###xml 221 224 218 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 229 237 226 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx-utrn</italic>
###xml 237 240 234 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 247 249 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 251 253 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 359 361 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 388 391 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 571 573 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 742 750 739 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx-utrn</italic>
###xml 750 753 747 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 970 972 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1253 1255 1247 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 1257 1259 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1320 1322 1314 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1605 1608 1599 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
Possibly up-regulation of utrophin isoforms partially compensates for the lack of brain dystrophins and thereby helps anchoring beta-dystroglycans. This idea agrees with previous studies of extraocular muscle fibres from mdx and mdx-utrn-/- mice [55, 56]. In contrast to the neuromuscular junction-specific localization of utrophin in normal skeletal muscle [55], in dystrophin-deficient mdx extraocular muscle the full-length isoform of utrophin of apparent 395 kDa is up-regulated in its relative expression and also found in n on-junctional regions of the sarcolemma [57]. This replacement of dystrophin Dp427 by the large utrophin isoform seems to spare a large proportion of the extraocular muscle population from degeneration. However, mdx-utrn-/- mice lacking both dystrophin and utrophin exhibit severe dystrophic changes in these muscle groups strongly suggesting that the endogenous up-regulation of utrophin protects extraocular muscle in dystrophinopathies [58]. A similar protective mechanism might occur in dystrophic brain regions. We could previously show that most members of the dystrophin super-family of proteins, which share the carboxy-terminal binding domain for beta-dystroglycan, exhibit very comparable biochemical properties [59, 60]. This was also confirmed for brain isoforms of dystrophin [61]. Since brain utrophins co-localize with the dystroglycan sub-complex in the forebrain, it seems likely that an up-regulation of utrophins anchors these components in Dp427- or Dp71-deficient membranes. Dp71 alone does not appear to properly oligomerize and anchor dystroglycans in mdx brain. Although Dp71 co-localizes with beta-dystroglycan, the lack of full-length brain dystrophin seems to trigger a disturbed organization of the dystroglycan sub-complex resulting in a drastic reduction in the extracellular dystroglycan isoform. These findings show that we still have an incomplete understanding of the individual functions of dystrophin isoforms and of the interaction between short and long dystrophins in different tissues.
###end p 30
###begin p 31
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 239 242 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 331 333 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 335 337 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 700 703 697 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 1118 1120 1115 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1175 1177 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1270 1272 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1273 1275 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1276 1278 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1374 1376 1371 1373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2064 2066 2058 2060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2179 2181 2173 2175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 207 212 <span type="species:ncbi:9606">human</span>
###xml 254 261 <span type="species:ncbi:9606">patient</span>
###xml 381 388 <span type="species:ncbi:9606">patient</span>
###xml 545 552 <span type="species:ncbi:9606">patient</span>
###xml 741 746 <span type="species:ncbi:9606">human</span>
###xml 1820 1828 <span type="species:ncbi:9606">patients</span>
###xml 2078 2086 <span type="species:ncbi:9606">patients</span>
###xml 2380 2388 <span type="species:ncbi:9606">children</span>
In contrast to established changes in the expression of dystrophins and utrophins in dystrophic brain [23,30,62], relatively little is known about the fate of dystrophin/utrophin-associated glycoproteins in human DMD brain. In contrast to mdx brain, DMD patient specimens appear to exhibit a reduction in beta-dystroglycan levels [16, 63]. However, representative surveys of large patient populations with a varying degree of mental retardation have not yet been performed making it difficult to compare findings from genetic animal models with patient data. In this respect, the finding presented in this study that the major brain dystrophin isoform Dp71 does not appear to properly oligomerize in mdx brain might also be relevant for the human disease condition. The lack of crosslinker-induced complex stabilization indicates that Dp71 might trigger abnormal anchoring of dystroglycans, although it is present at normal concentrations. This in turn might destabilize certain brain structures and/or signal transduction pathways normally relying on the integrity of brain dystrophin-glycoprotein complexes. Since Ca2+-levels were found to be abnormal in dystrophic brain [64], similar pathophysiological changes, as suggested to be involved in muscular degeneration [19,20,21], could also render certain brain cells more susceptible to necrosis. An increased influx of Ca2+-ions might trigger cell destruction not only in Dp71-deficient cells but also in cellular structures with Dp71 molecules not capable of properly forming complexes with beta-dystroglycan. In the dystrophic forebrain, abnormal anchoring of dystroglycans might therefore affect the proper establishment of the blood-brain barrier. However, since the cognitive impairment in DMD is non-progressive and exhibits great variations between individual patients, only a sub-population of brain cells may be affected by this pathophysiological mechanism. Deletions in the exon 45-52 region of the DMD gene have been reported to be associated with an increased incidence of cognitive abnormalities [24]. In these patients only the expression of the Dp 427 and Dp140 isoforms is impaired, but not the Dp71 protein [65]. Thus, probably a combination of different primary genetic defects in the DMD gene and variations in compensatory mechanisms result in the different degrees of mental insufficiencies in dystrophic children.
###end p 31
###begin title 32
Conclusions
###end title 32
###begin p 33
###xml 623 626 617 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
In conclusion, this report demonstrates that beta-dystroglycan is not present at high concentrations in central neurons of the forebrain region, but seems to be mostly located at the interface between endothelial cells and glia. These structures possibly represent endfeet on astrocytes at the blood-brain barrier. In dystrophic forebrain, beta-dystroglycan expression is not drastically affected, possibly due to the up-regulation of utrophin isoforms which partially compensate for the deficiency in brain dystrophins. Chemical crosslinking analysis showed that Dp71 exists in contrast to its normally oligomeric form in mdx brain as a monomeric protein. Thus, the lack in brain dystrophins does not necessarily lead to a loss in all associated glycoproteins and possibly abnormal oligomerization of the brain dystrophin might play a role in the molecular pathogenesis of abnormal brain functions in muscular dystrophy.
###end p 33
###begin title 34
Materials and methods
###end title 34
###begin title 35
Materials
###end title 35
###begin p 36
Fluorescein-, rhodamine- or peroxidase-conjugated secondary antibodies were purchased from Boehringer Mannheim (Lewis, East Sussex, UK). Commercially available primary antibodies were from Novocastra Laboratories Ltd. (Newcastle upon Tyne, UK), Upstate Biotechnology (Lake Placid, NY, USA) and Sigma Chemical Company (Poole, Dorset, UK), and Texas Red-labeled alpha-bungarotoxin was purchased from Molecular Probes Europe BV (Leiden, The Netherlands). Superfrost Plus positively-charged microscope slides were from Menzel Glaesser (Braunschweig, Germany). Fuji Neopan 400ASA B/W photographic film was obtained from Fuji Photo Film Co. (Tokyo, Japan) and Kodacolor Gold 400ASA VR film from Eastman Kodak Company (Rochester, NY). Protease inhibitors and acrylamide were purchased from Boehringer Mannheim (Lewis, East Sussex, UK). Peroxidase-conjugated lectins were purchased from EY Labs (San Mateo, CA, USA). Western blotting chemiluminescence substrates and chemical crosslinkers were obtained from Pierce & Warriner (Chester, Cheshire, UK). Immobilon-P nitrocellulose was from Millipore Corporation (Bedford, MA, USA). All other chemicals were of analytical grade and purchased from Sigma Chemical Company (Poole, Dorset, UK).
###end p 36
###begin title 37
Antibodies
###end title 37
###begin p 38
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 456 457 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 521 522 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 524 525 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 949 951 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 1061 1062 1042 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1357 1359 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 1401 1403 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
Monoclonal and polyclonal antibodies employed in this study were characterized as previously described [66, 67]. Monoclonal antibodies NCL-43 against beta-dystroglycan, NCL-a-SARC against alpha-sarcoglycan, DYS-1 to the Dp427 rod-domain, DYS-2 to the Dp427 carboxy-terminus, NCL-DRP1 to the carboxy -terminus of full-length utrophin and NCL-SPEC2 against spectrin were from Novocastra Laboratories Ltd. (Newcastle upon Tyne, UK). Monoclonal antibodies VIA41 to alpha-dystroglycan and c464.6 to the alpha-subunit of the Na+/K+-ATPase were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Polyclonal antibodies to von Willebrand factor, laminin and the glial fibrillary acidic protein, as well as monoclonal antibody NR4 to the neurofilament of apparent 68 kDa were obtained from Sigma Chemical Company (Poole, Dorset, UK). A polyclonal antibody which recognizes the carboxy-terminal domain of the utrophin isoforms Up395, Up116 and Up71 [68] was a generous gift of Dr. Steve Winder (University of Glasgow). Monoclonal antibody IIID5 against the alpha1-subunit of the dihydropyridine receptor was a generous gift of Dr. Kevin P. Campbell (University of Iowa, Iowa City, IA). An antibody to the extreme carboxy-terminus of alpha-sarcoglycan was raised by 4 monthly injections of a peptide representing the last 15 residues of the carboxy-terminus [69] using a standard immunization protocol [70]. The peptide had been synthesized and coupled to KLH carrier by Research Genetics (Huntington, AL).
###end p 38
###begin title 39
Animal models
###end title 39
###begin p 40
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mdx</italic>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 548 565 548 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tibialis anterior</italic>
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
Muscle and brain samples from the mdx mouse, which lacks the Dp427 isoform of dystrophin due to a point mutation in exon 23 [38], and from the mdx-3cv mouse, which has a mutation in exon 65 that affects the splicing of both the 4.8 and 14 kb dystrophin mRNAs causing a loss of all dystrophin isoforms including the major brain dystrophin isoform Dp71 [39], were a generous gift from Dr. Harald Jockusch (Department of Developmental Biology, University of Bielefeld, Germany). For immunofluorescence microscopy, tissue specimens were taken from the tibialis anterior muscle and the forebrain region, quick-frozen in liquid nitrogen-cooled isopentane, transported on dry ice and stored at -70degreesC prior to cryosectioning. For immunoblot analysis, total brain and bulk skeletal muscle were dissected, quick-frozen in liquid nitrogen, transported in a container with dry ice and then stored at -70degreesC prior to homogenization.
###end p 40
###begin title 41
Immunofluorescence microscopy
###end title 41
###begin p 42
###xml 389 391 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
For immunolabeling of muscle and brain tissue sections, 12 mum cryosections were prepared using a standard cryostat (Microm, Heidelberg, Germany) and mounted on Superfrost Plus positively-charged microscope slides. Fixation, blocking, incubation with primary antibodies, washing steps, incubation with secondary antibodies, as well as photography was performed by established methodology [55]. Photographs were taken on Fuji Neopan 400ASA B/W photographic film or Kodak Gold Kodacolor 400ASA VR film. For double-staining procedures, a mixture of the appropriate primary antibodies were applied to tissue sections for 1 h at 37degreesC, cryosections washed, and then separately incubated for 30 min each with the appropriate secondary antibodies. In case of antibodies which had been generated in the same animal species, photographic images were obtained from concurrent areas in serial sections, and the labeling results overlayed.
###end p 42
###begin title 43
Isolation of muscle and brain membranes
###end title 43
###begin p 44
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 834 836 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 446 453 <span type="species:ncbi:3847">soybean</span>
###xml 844 850 <span type="species:ncbi:9913">bovine</span>
In order to compare the relative expression levels of members of the dystrophin-glycoprotein complex by immunoblotting, established protocols for the isolation of microsomal membranes from skeletal muscle [45] and brain [71] were employed. To minimize proteolytic degradation of membrane proteins, all buffers contained a protease inhibitor cocktail (0.2 mM pefabloc, 1.4 muM pepstatin, 0.15 muM aprotinin, 0.3 muM E-64, 1 muM leupeptin, 0.5 muM soybean trypsin inhibitor, and 1 mM EDTA) and all procedures were performed in a cold room at 0-4degreesC. Membrane pellets were resuspended at a protein concentration of 10 mg/ml and used immediately for gel electrophoretic analysis or quick-frozen in liquid nitrogen and then stored at -70degreesC prior to further usage. Protein concentration was determined by the method of Bradford [72] using bovine serum albumin as a standard.
###end p 44
###begin title 45
Chemical crosslinking analysis
###end title 45
###begin p 46
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 278 279 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 418 419 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 755 757 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
Chemical crosslinking was performed as previously described in detail [45, 66]. Microsomes (1 mg protein) were diluted to a final volume of 500 mul with 50 mM HEPES, pH 8.0 at 25degreesC. Using a stock solution of 5 mg/ml chemical crosslinker, bis-sulfosuccinimidyl-suberate (BS3) was added to the membrane suspension at a final concentration of 200 mug cross-linker per mg membrane protein. Since the cross -linker BS3 is water-soluble, it was dissolved in 50 mM citrate buffer, pH 5.0 in order to retard hydrolysis. Samples were incubated for 30 min with constant agitation at 25degreesC and then the crosslinking reactions terminated by the addition of 50 mul of 1 M ammonium acetate per ml reaction mixture. An equal volume of reducing sample buffer [73] was added and the solution incubated for 15 min at 37degreesC before being subjected to electrophoretic separation.
###end p 46
###begin title 47
Gel electrophoresis, lectin staining and immunoblotting
###end title 47
###begin p 48
###xml 327 329 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 331 333 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 512 514 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 669 671 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 806 808 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 887 889 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 572 588 <span type="species:ncbi:3496">Maclura pomifera</span>
Gel electrophoretic separation using 5% or 7% (w/v) resolving gels with a 5% (w/v) stacking gel in the presence of sodium dodecyl sulfate and dithiotreitol was performed for 200 Vh employing a Mini-MP3 electrophoresis system from Bio-Rad Laboratories (Hempel Hempstead, Herts., UK), whereby 25 mug protein was loaded per well [66, 73]. Chemically crosslinked samples were separated on gels lacking a stacking gel system. Nitrocellulose replica of polyacrylamide gels were produced as described by Towbin et al. [74]. Blot overlays with peroxidase-conjugated lectins (MPA, Maclura pomifera lectin; WGA, Tritium vulgaris lectin) were carried out as previously described [75]. For immunolabeling, nitrocellulose sheets were blocked and incubated with primary and secondary antibodies as previously described [45]. Immunodecoration was evaluated by the enhanced chemiluminescence technique [76]. Densitometric scanning of enhanced chemiluminescence blots was performed on a Molecular Dynamics 300S computing densitometer (Sunnyvale, CA) with ImageQuant V3.0 software.
###end p 48
###begin title 49
Acknowledgements
###end title 49
###begin p 50
Research was supported by project grants from the Irish Health Research Board (HRB-01/98) and Enterprise Ireland, Dublin (SC/2000/386), and a European travel grant from the Royal Society, London and the Royal Irish Academy, Dublin. The authors would like to thank Drs. H. Jockusch (University of Bielefeld, Germany), K.P. Campbell (University of Iowa, IA, USA) and S. Winder (University of Glasgow, Scotland) for providing our lab with animal models and antibodies.
###end p 50
###begin article-title 51
Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage.
###end article-title 51
###begin article-title 52
The dystrophinopathies: an alternative to the structural hypothesis.
###end article-title 52
###begin article-title 53
Towards an understanding of the dystrophin-glycoprotein complex: linkage between the extracellular matrix and the subsarcolemmal membrane cytoskeleton.
###end article-title 53
###begin article-title 54
Plasma membrane cytoskeleton of muscle: a fine structural analysis.
###end article-title 54
###begin article-title 55
From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy.
###end article-title 55
###begin article-title 56
Dystroglycan inside and out.
###end article-title 56
###begin article-title 57
Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex.
###end article-title 57
###begin article-title 58
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
Two forms of mouse syntrophin, a 58 kD dystrophin-associated protein, differ in primary structure and tissue distribution.
###end article-title 58
###begin article-title 59
beta-Dystrobrevin, a new member of the dystrophin familiy.
###end article-title 59
###begin article-title 60
Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix.
###end article-title 60
###begin article-title 61
A new model for the interaction of dystrophin with F-actin.
###end article-title 61
###begin article-title 62
Identification and characterization of the dystrophin anchoring site of beta-dystroglycan.
###end article-title 62
###begin article-title 63
The membrane-cytoskeleton interface: the role of dystrophin and utrophin.
###end article-title 63
###begin article-title 64
Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma.
###end article-title 64
###begin article-title 65
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice.
###end article-title 65
###begin article-title 66
Reduction of brain beta-dystroglycan in Duchenne muscular dystrophy but not the mdx animal model.
###end article-title 66
###begin article-title 67
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Decreased osmotic stability of dystrophin-less muscle cells from mdx mouse.
###end article-title 67
###begin article-title 68
Dystrophin protects the sarcolemma from stresses developed during muscle contraction.
###end article-title 68
###begin article-title 69
Increased calcium influx in dystrophic muscle.
###end article-title 69
###begin article-title 70
Calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes.
###end article-title 70
###begin article-title 71
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 81 83 81 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibres detected with Ca2+-activated K+ channels.
###end article-title 71
###begin article-title 72
Role of dystrophin isoforms and associated glycoproteins in muscular dystrophy (review).
###end article-title 72
###begin article-title 73
The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle?
###end article-title 73
###begin article-title 74
Brain dystrophin, neurogenetics and mental retardation.
###end article-title 74
###begin article-title 75
The structural and functional diversity of dystrophin.
###end article-title 75
###begin article-title 76
###xml 34 39 <span type="species:ncbi:9606">human</span>
Characterization of DRP2, a novel human dystrophin homologue.
###end article-title 76
###begin article-title 77
Primary structure of dystrophin-related protein.
###end article-title 77
###begin article-title 78
Full-length and short forms of utrophin, the dystrophin-related protein.
###end article-title 78
###begin article-title 79
Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons.
###end article-title 79
###begin article-title 80
###xml 55 58 <span type="species:ncbi:10116">rat</span>
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Detection of dystrophin in the postsynaptic density of rat brain and deficiency in a mouse model of Duchenne muscular dystrophy.
###end article-title 80
###begin article-title 81
Dystroglycan in the cerebellum is a laminin alpha 2-chain binding protein in the glial -vascular interface and is expressed in Purkinje cells.
###end article-title 81
###begin article-title 82
The demonstration of immunoreactive dystrophin and its developmental expression in perivascular astrocytes.
###end article-title 82
###begin article-title 83
###xml 47 50 <span type="species:ncbi:10116">rat</span>
Beta-dystroglycan: subcellular localisation in rat brain and detection of a novel immunologically related, postsynaptic density-enriched protein.
###end article-title 83
###begin article-title 84
###xml 54 60 <span type="species:ncbi:9913">bovine</span>
Association of the dystroglycan complex isolated from bovine brain synaptosomes with proteins involved in signal transduction.
###end article-title 84
###begin article-title 85
Different dystrophin-like complexes are expressed in neurons and glia.
###end article-title 85
###begin article-title 86
The subcellular distribution of chromosome 6-encoded dystrophin-realted protein in the brain.
###end article-title 86
###begin article-title 87
Interaction of chromosome-6-encoded dystrophin related protein with the extracellular matrix.
###end article-title 87
###begin article-title 88
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.
###end article-title 88
###begin article-title 89
New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin.
###end article-title 89
###begin article-title 90
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Passive avoidance behaviour deficit in the mdx mouse.
###end article-title 90
###begin article-title 91
Retention deficits at long delays in spontaneous alteration and bar-pressing tasks.
###end article-title 91
###begin article-title 92
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Behavioral characterization of mdx3cv mice deficient in C-terminal dystrophins.
###end article-title 92
###begin article-title 93
###xml 69 74 <span type="species:ncbi:9606">human</span>
Unexpected immunoreactivities of intermediate filament antibodies in human brain-tumors.
###end article-title 93
###begin article-title 94
Differentiation of endothelium.
###end article-title 94
###begin article-title 95
###xml 57 58 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 89 95 <span type="species:ncbi:9986">rabbit</span>
Crosslinking analysis of the ryanodine receptor and alpha1 - dihydropyridine receptor in rabbit skeletal muscle triads.
###end article-title 95
###begin article-title 96
Dystrophinopathies.
###end article-title 96
###begin article-title 97
Intellectual impairment in muscular dystrophy.
###end article-title 97
###begin article-title 98
Psychometric studies in muscular dystrophy type IIIa (Duchenne).
###end article-title 98
###begin article-title 99
Cognitive impairment in Duchenne muscular dystrophy.
###end article-title 99
###begin article-title 100
Brain morphology in Duchenne muscular dystrophy.
###end article-title 100
###begin article-title 101
###xml 91 94 <span type="species:ncbi:10116">rat</span>
 Immunolocalization of dystrobrevin in the astrocytic endfeet and endothelial cells in the rat cerebellum.
###end article-title 101
###begin article-title 102
###xml 76 79 <span type="species:ncbi:10116">rat</span>
Beta-dystroglycan localization in the photoreceptor and Muller cells in the rat retina revealed by immunoelectron microscopy.
###end article-title 102
###begin article-title 103
Current knowledge of dystrophin and dystrophin-associated proteins in the retina.
###end article-title 103
###begin article-title 104
Dystrobrevin localization in photoreceptor axon terminals and at blood-ocular barrier sites.
###end article-title 104
###begin article-title 105
Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle.
###end article-title 105
###begin article-title 106
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Skeletal muscle-specifi c expression of utrophin transgene rescues utrophin-dystrophin deficient mice.
###end article-title 106
###begin article-title 107
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Association of dystrophin -related protein with dystrophin-associated proteins in mdx mouse.
###end article-title 107
###begin article-title 108
###xml 65 69 <span type="species:ncbi:10090">mice</span>
The sparing of extraocular muscle in dystrophinopathy is lost in mice lacking utrophin and dystrophin.
###end article-title 108
###begin article-title 109
Dystrophin constitutes five percent of membrane cytoskeleton in skeletal muscle.
###end article-title 109
###begin article-title 110
Membrane cytoskeletal characterisation of utrophin in highly purified sarcolemma vesicles.
###end article-title 110
###begin article-title 111
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
Rabbit brain and muscle isoforms containing the carboxy-terminal domain of 427 kDa skeletal muscle dystrophin exhibit similar biochemical properties.
###end article-title 111
###begin article-title 112
###xml 43 48 <span type="species:ncbi:9606">human</span>
Deficiency of brain synaptic dystrophin in human Duchenne muscular dystrophy.
###end article-title 112
###begin article-title 113
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Distribution of dystrophin and dystrophin-associated protein 43DAG (beta-dystroglycan) in the central nervous system of normal controls and patients with Duchenne muscular dystrophy.
###end article-title 113
###begin article-title 114
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
Regulation of intracellular free calcium in normal and dystrophic mouse cerebellar neurons.
###end article-title 114
###begin article-title 115
Dp140: a novel 140 kDa CNS transcript from the dystrophin locus.
###end article-title 115
###begin article-title 116
###xml 40 46 <span type="species:ncbi:9986">rabbit</span>
Oligomerization of beta-dystroglycan in rabbit diaphragm and brain as revealed by chemical crosslinking.
###end article-title 116
###begin article-title 117
Dystrophin glycoprotein complex is highly enriched in skeletal muscle sarcolemma.
###end article-title 117
###begin article-title 118
Adhesion-dependent tyrosine phosphorylation of (beta)-dystroglycan regulates its interaction with utrophin
###end article-title 118
###begin article-title 119
Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy.
###end article-title 119
###begin article-title 120
Antibodies. A Laboratory Manual.
###end article-title 120
###begin article-title 121
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 98 104 <span type="species:ncbi:9986">rabbit</span>
Solubilization and biochemical characterization of the high-affinity [3H] ryanodine receptor from rabbit brain membranes.
###end article-title 121
###begin article-title 122
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
###end article-title 122
###begin article-title 123
###xml 12 28 <span type="species:ncbi:10760">bacteriophage T7</span>
Cleavage of bacteriophage T7 early RNAs and proteins on slab gels.
###end article-title 123
###begin article-title 124
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
###end article-title 124
###begin article-title 125
The sea urchin egg receptor for sperm: isolation and characterization of the intact, biologically active receptor.
###end article-title 125
###begin article-title 126
Analysis of membrane proteins by Western blotting and enhanced chemiluminescence.
###end article-title 126

